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Phosphatidylinositol 3-kinaseInsulin receptor substrate-1 (IRS-1) is a key protein in the insulin-like growth factor (IGF) signaling whose
tyrosine phosphorylation by the type 1 IGF receptor is necessary for the recruitment and activation of the
downstream effectors. Through the analysis of cross-talks occurring between different tyrosine kinase
receptor-dependent signaling pathways, we investigated how two growth factors [epidermal growth factor
(EGF) and ﬁbroblast growth factor (FGF)] could modulate the IGF-I-induced IRS-1 tyrosine phosphorylation
and its downstream signaling. EGF and FGF inhibited IGF-I-stimulated tyrosine phosphorylation of IRS-1 and
the subsequent IGF-I-induced phosphatidylinositol 3-kinase (PI 3-kinase) activity. These EGF- and FGF-
inhibitory effects were dependent on both PI 3-kinase and protein kinase D1 (PKD1) signaling pathways
but independent on the extracellular signal-regulated kinase (ERK) pathway. PKD1, which was activated in-
dependently of the PI 3-kinase pathway, associated with IRS-1 in response to EGF or FGF. Unlike PI 3-kinase,
PKD1 did not mediate the EGF- or FGF-induced-IRS-1 serine 307 phosphorylation which was described to in-
hibit IRS-1. Interestingly, speciﬁc inhibition of either PI 3-kinase or PKD1 totally impaired EGF- or FGF-
induced inhibition of IGF-I-stimulated IRS-1 tyrosine phosphorylation. This indicated that serine 307 phos-
phorylation of IRS-1 is not sufﬁcient per se to inhibit the IGF signaling pathway and demonstrated for the
ﬁrst time that the negative regulation of IRS-1 requires the coordinated action of PI 3-kinase and PKD1.
This further suggests that PKD1 may be an attractive target for innovative strategies that target the IGF sig-
naling pathway.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Insulin-like growth factors (IGF-I and -II) are potent polypeptide
mitogens implicated in cell proliferation, differentiation and survival
(for review [21]). They are produced bymost tissues and their biological
effects are transmitted via the type I IGF receptor (IGF-IR) which is a
heterotetrameric transmembrane glycoprotein composed of two extra-
cellular α-subunits and two transmembrane β-subunits and shares
strong homology with the insulin receptor (IR) [47]. Binding of IGFs to
the α-subunits induces the autophosphorylation and the activation of
the tyrosine kinase domain of the β-subunits which phosphorylates
onto tyrosine residues several intracellular targets such as insulin
receptor substrate-1 (IRS-1) [44].tracellular signal-regulated ki-
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l rights reserved.IRS-1 is a member of a family comprising four related proteins,
IRS-1 to -4 [24,25,40,42,44,45] that plays a unique role in the IGF sig-
naling pathway and particularly in most breast tumors with a domi-
nant function over the other isoforms of the family [19]. Upon its
IGF-IR-induced phosphorylation onto 18 potential tyrosine residues
[13,55], IRS-1 associates with Src homology 2 (SH2) domain-
containing proteins like Shc, Nck, Grb2, Grb10 and the p85 regulatory
subunit of phosphatidylinositol 3-kinase (PI 3-kinase). These subtle
protein–protein interactions provided by IRS-1 initiate intracellular
signaling pathways that result in the speciﬁc biological activities of
the IGFs (for review [52]). IRS-1 therefore represents a centerpiece
in the IGF signaling pathway and its regulation, either positive or nega-
tive, signiﬁcantly affects the IGF pathway. Thus, increased IRS-1 expres-
sion induces cell transformation [18] and impairs inhibitory
mechanisms affecting the IGF signaling pathway [23]. However, de-
creased IRS-1 expression reduces cell viability [33]. Moreover, the ex-
tent of IRS-1 tyrosine phosphorylation can be modulated by several
mechanisms including proteasome-mediated degradation [26],
phosphatase-mediated dephosphorylation [9,32], and serine/threonine
phosphorylation (for review see [12]). This last process is relatively
complex since it can play opposite roles depending on the considered
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phorylation of IRS-1 is more commonly described as a negative regula-
tory signal by decreasing IRS-1 afﬁnity for its upstream activating
tyrosine kinase receptor [2,34].
Protein kinase D1 (PKD1), which includes human protein kinase
Cμ (PKCμ) and its mouse homolog protein kinase D (PKD), is a novel
serine/threonine kinase involved in signal transduction pathways ini-
tiated by diacylglycerol (DAG) and the protein kinase C (PKC) family
[20,48,50]. PKD1 was initially described as an atypical member of the
PKC family [20]. However, PKD1 possesses distinct substrate speciﬁcity
[48,49] and has therefore recently been classiﬁed as a novel subgroup of
the calcium/calmodulin-dependent kinase (CAMK) family [39]. PKD1,
which is expressed in most tissues [20,48], has actually been reported
to play a role in cell proliferation [37,53,58] and survival [43]. However,
little is known about the downstream effectors regulated by PKD1.
Since IGFs are potent determinants in cancer incidence [14,17],
knowledge of their regulatory mechanisms is essential. Therefore,
we took advantage of an adenocarcinoma-derived breast cancer cell
line, MCF-7, that expresses a large range of growth factor receptors
and in which IRS-1 is a crucial IGF-I-activated signaling molecule
[19], to investigate the molecular processes that modulate the tyro-
sine phosphorylation of IRS-1 in the context of signaling pathways
cross-talks.
We demonstrated that IGF-I-induced IRS-1 tyrosine phosphoryla-
tion and subsequent PI 3-kinase activation were inhibited by epider-
mal growth factor (EGF) or ﬁbroblast growth factor (FGF) treatment.
This down-regulation of the IGF signaling, which takes place at the
level of IRS-1, requires the concomitant action of PI 3-kinase and pro-
tein kinase D1 which both associate with IRS-1. Therefore, our results
identiﬁed PKD1 as a new regulatory partner of IRS-1 implicated in the
ﬁne control of the IGF-I signal transduction efﬁciency.
2. Materials and methods
2.1. Antibodies and materials
Anti-phosphotyrosine, anti-Akt1, anti-IRS-1, and anti-phospho-IRS-1
(Ser307) antibodies used for immunoblotting were purchased from
Upstate Biotechnology-Millipore (Lake Placid, NY). Anti-IRS-1 and anti-
p85-subunit of PI 3-kinase antibodies used for PI 3-kinase assay and im-
munoprecipitationwere a kind gift from J-F Tanti (INSERM, Nice, France)
or were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) like
anti-PKD1, anti-actinin and anti-actin antibodies. Anti-phospho-PKD1
(Ser744/748), anti-phospho-Akt (Thr308) and anti-ERK1/2 antibodies
were form Cell Signaling (Danvers, MA). EGF and bFGF were from
PeproTech (Rocky Hill, NJ), and IGF-I from GroPep (Adelaide,
Australia). Gö6983, Gö6976 and GF109203X were from Calbiochem
(La Jolla, CA), wortmannin was from Sigma-Aldrich (Saint-Quentin
Fallavier, France) and PD98059 was from Cell Signaling Technology
(Danvers, MA). Protein A-Sepharose was from GE Healthcare Life
Sciences (Orsay, France). PKD1 siRNA (sc-36245) and control siRNA
(sc-37007) were from Santa Cruz Biotechnology (Santa Cruz, CA).
All other biochemicals were from Sigma-Aldrich (Saint-Quentin
Fallavier, France) or ICN (Orsay, France).
2.2. Cell culture
TheMCF-7 cell line was grown to 80–85% conﬂuence in Dulbecco's
modiﬁed Eagle's medium supplemented with 10% fetal bovine serum
(FBS), 100 units/mL penicillin and 100 μg/mL streptomycin. Before each
experiment, cells were starved in media without serum for 16–24 h.
2.3. siRNA transfection
siRNA transfection was done according to manufacturer's proto-
col. Brieﬂy, 3×105 cells were seeded per well in 2 mL antibiotic-freeDMEM supplemented with 10% FBS and incubated for 24 h. For
each well, 1 μg of siRNA and 8 μL of siRNA transfection reagent,
each diluted in 100 μL siRNA transfection medium, were combined,
incubated for 45 min at room temperature and then applied to the
cells in a ﬁnal volume of 1 mL siRNA transfection medium. After 7 h
of incubation at 37 °C, DMEM supplemented with 10% FBS was
added and cells cultured for an additional 18–24 h at 37 °C before
use.
2.4. Western immunoblotting
MCF-7 cells were cultured as described and treated for different
periods of time with or without EGF or FGF before being acutely stimu-
lated or not for 5 min with IGF-I. Cells were then solubilized in buffer A
(20 mM Tris, pH 7.4, 137 mM NaCl, 100 mM NaF, 10 mM EDTA, 2 mM
Na3VO4, 10 mMpyrophosphate, 1 mMPMSF, 100 U/mL aprotinin) con-
taining 1% Nonidet P-40 (NP-40), and proteins separated by SDS-PAGE
and transferred to polyvinylidene diﬂuoride (PVDF) sheets. These were
incubated with the speciﬁc antibodies for 1 h at room temperature or
overnight at 4 °C and revealed by chemiluminescence (ECL,
Amersham).
2.5. Immunoprecipitation
Cells were washed with ice-cold buffer A and solubilized as de-
scribed above. Supernatants from solubilized cells were then immu-
noprecipitated for 2 h at 4 °C with anti-IRS-1 antibodies pre-
adsorbed to protein A-Sepharose. The immune pellets were washed
three times with buffer A, treated with Laemmli buffer, boiled for
10 min, and separated by 7.5% acrylamide SDS-PAGE. Proteins were
then transferred to PVDF sheets and immunoblotted with anti-PKD1
and anti-IRS-1 antibodies as described above.
2.6. Determination of PI 3-kinase activity
Lysates from cells treated as above were incubated for 2 h at 4 °C
with anti-IRS-1 or anti-p85 antibodies coupled to protein A-
Sepharose beads. Thereafter, immune pellets were successively
washed twice with each of the three following buffers: (a) PBS con-
taining 1% Nonidet P-40 and 200 μM Na3VO4; (b) 100 mM Tris
pH 7.4, 0.5 M LiCl, 200 μM Na3VO4; and (c) 10 mM Tris pH 7.4,
100 mM NaCl, 1 mM EDTA, 200 μM Na3VO4. Immunoprecipitated
PI 3-kinase activity was measured in the immune pellets by in vitro
phosphorylation of phosphatidylinositol (PI) [16,8]. The reaction
products were separated by thin layer chromatography on silica plates
in methanol/chloroform/ammoniac buffer. After autoradiography,
PI 3-kinase activity was quantiﬁed by Cerenkov analysis of the
spots corresponding to PI 3-P.
3. Results
3.1. EGF and FGF inhibit the IGF-I-induced tyrosine phosphorylation of
IRS-1 in MCF-7 cells
Analysis of signaling pathway interactions is an experimental ap-
proach that allows identifying intracellular regulatory mechanisms.
Using this strategy, we searched to determine molecular processes
that may regulate the IGF-I signaling pathway. MCF-7 cells, which ex-
press a wide range of tyrosine kinase receptors, were pretreated or
not with EGF or FGF for different periods of time (5 to 60 min) and
then acutely stimulated for 5 min with IGF-I. Cells were lysed and
the tyrosine phosphorylation state of IRS-1 was analyzed by western
blot using an anti-phosphotyrosine antibody. Tyrosine phosphoryla-
tion of IRS-1 was undetectable at the basal state but was strongly in-
creased after 5 min of IGF-I stimulation (Fig. 1A). EGF or FGF
pretreatment markedly inhibited the IGF-I-induced IRS-1 tyrosine
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Fig. 1. EGF or FGF pretreatment inhibits IGF-I-induced IRS-1 tyrosine phosphorylation and IGF-stimulated PI 3-kinase activity. Cells were incubated for different periods of time
(5–60 min) with EGF (40 ng/mL) or FGF (5 ng/mL) and then stimulated for 5 min with IGF-I (22.5 ng/mL). A. Cells were lysed and proteins separated by SDS-PAGE, transferred
to PVDF sheets and immunoblotted with anti-phosphotyrosine or anti-actin antibodies as described in Materials and methods. The autoradiograms presented are those of typical
experiments conducted in duplicate. Bars represent quantitative analysis of total tyrosine phosphorylated IRS-1 under each set of conditions, corrected for background, and
expressed as percentages of phosphotyrosylated IRS-1 measured after 5 min of IGF-I stimulation without any pretreatment with EGF or FGF (control). Results are the means
±SEM for four independent experiments (*, Pb0.01). B. Cells were homogenized and proteins immunoprecipitated with anti-IRS-1 (left graphs) or anti-p85 subunit of PI 3-
kinase (right graphs) antibodies. The immune pellets were used to measure PI 3-kinase activity as described under Materials and methods. Results are the means±SEM for ﬁve
independent experiments. The results are presented as raw data (cpm) (top graphs) or are expressed as percentages of the activity measured after 5 min of IGF-I stimulation with-
out any pretreatment with EGF or FGF (control) (bottom graphs).
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pretreatment (55% and 62% respectively) and then remained stable
for at least 60 min. Inhibition of IGF-I-induced IRS-1 tyrosinephosphorylation was not a consequence of a decreased IRS-1 protein
content [23] nor of a reduced IGF-I-induced autophosphorylation of
the IGF-IR ß-subunits (data not shown).
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Fig. 2. EGF and FGF stimulate ERK and PI 3-kinase activities in MCF-7 cells. Cells were
stimulated or not with EGF (40 ng/mL) or FGF (5 ng/mL) for different periods of time
(5–60 min). A. Cells were lysed and proteins separated by SDS-PAGE, transferred to
PVDF sheets and immunoblotted with anti-ERK2 or anti-actinin antibodies as de-
scribed in Materials and methods. The autoradiogram presented is one of typical exper-
iments. B. Cells were homogenized and proteins immunoprecipitated with an antibody
directed against the p85 subunit of PI 3-kinase. PI 3-kinase assay was performed on the
immune pellets as described under Materials and methods. Results are expressed rela-
tive to basal activity measured in non-stimulated cells and are the means±SEM for
three independent experiments.
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MCF-7 cells
Since IGF-I-stimulated PI 3-kinase activity is dependent upon the
tyrosine phosphorylation state of IRS-1, we asked whether EGF or
FGF pretreatment affects subsequent IGF-I-induced PI 3-kinase activity.
Thus, MCF-7 cells were pretreated or not with EGF or FGF for different
periods of time (5 to 60 min) and then stimulated for 5 min with
IGF-I. Cellswere lysed, proteins solubilized and PI 3-kinase activitymea-
sured in immunoprecipitates obtained with antibodies directed against
either IRS-1 (Fig. 1B, left graphs) or the p85 regulatory subunit of PI 3-
kinase (Fig. 1B, right graphs). IGF-I stimulation (i.e. without any pre-
treatment with EGF or FGF) strongly stimulated IRS-1-associated
(54-±16.5 fold increase; n=6) and total (6-±2.2 fold increase;
n=7) PI 3-kinase activity (Fig. 1B, top graphs). Remarkably, EGF or
FGF pretreatment modulated IGF-I-stimulated PI 3-kinase activity
with almost identical inhibitory time courses (Fig. 1B, bottom graphs).
In fact, on the one hand, inhibition of IGF-I-stimulated total PI 3-
kinase activity (measured in anti-p85 immunoprecipitates) induced
by EGF or FGF pretreatment was rapid, with maximal effect (approxi-
mately 40%) obtained after 15 min of pretreatment, and persisted for
at least 60 min (Fig. 1B, right bottom graph). On the other hand, EGF-
and FGF-induced inhibition of IGF-I-stimulated IRS-1-associated PI 3-
kinase activity (measured in anti-IRS-1 immunoprecipitates) was also
rapid (about 35% after 5 min of pretreatment) but biphasic (Fig. 1B,
left bottom graph). Indeed, this inhibition decreased after 15 min of
EGF or FGF pretreatment and then increased again to 30–40% after 30
to 60 min of pretreatment.
3.3. EGF and FGF inhibit the IGF-I-induced IRS-1 tyrosine phosphoryla-
tion by a PI 3-kinase dependent signaling pathway
Since EGF or FGF pretreatment affects both IGF-I-induced IRS-1 ty-
rosine phosphorylation and IGF-I-stimulated PI 3-kinase activity, we
asked whether one (or both) of the two major signaling pathways
(i.e. PI 3-kinase and extracellular-regulated kinase (ERK) signaling
pathways), commonly activated downstream of tyrosine kinase re-
ceptors, might account for such effects. First of all, we analyzed the
activation state of these two signaling pathways in response to EGF
and FGF in MCF-7 cells. As we previously demonstrated [23], both
EGF and FGF activated ERK with similar time courses in MCF-7 cells
(Fig. 2A). Maximal activity was obtained after 7 min of incubation
and remained over basal values for at least 1 h. EGF and FGF also similar-
ly stimulated PI 3-kinase activity in MCF-7 cells (Fig. 2B). Maximal PI 3-
kinase activity (1.8- and 2.5-fold respectively) was measured after
5–10min of incubation and was followed by a rapid decrease to basal
values.
To determine whether EGF- and FGF-stimulated PI 3-kinase and/
or ERK activities could mediate the negative regulation of the IGF-I-
induced IRS-1 tyrosine phosphorylation, cells were incubated with
or without wortmannin (Fig. 3A) or PD98059 (Fig. 3B), two speciﬁc
inhibitors of PI 3-kinase and MEK (activating kinase upstream of
ERK), respectively. Cells were then pretreated or not with EGF or
FGF for different periods of time before being acutely stimulated for
5 min with IGF-I and analyzed for the tyrosine phosphorylation
state of IRS-1. Tyrosine phosphorylation of IRS-1, that was barely de-
tectable in basal conditions (untreated cells), was strongly stimulated
by IGF-I (Fig. 3A and B) and affected by neither wortmannin (Fig. 3A)
nor PD98059 preincubation (Fig. 3B). As previously shown (Fig. 1),
pretreatment with EGF or FGF decreased the IGF-I-induced IRS-1 ty-
rosine phosphorylation (Fig. 3A and B). Treatment with wortmannin
strongly impaired this inhibition (Fig. 3A) whereas PD98059 did not
(Fig. 3B). Phosphorylation state analysis of Akt (an activated down-
stream target of PI 3-kinase) and ERK2 conﬁrmed that wortmannin
speciﬁcally inhibited only the PI 3-kinase signaling pathway without
affecting the MEK/ERK pathway (Fig. 3C).Therefore, taken all together, these results demonstrate that EGF
and FGF inhibit the IGF-I-induced tyrosine phosphorylation of IRS-1
by a PI 3-kinase-dependent and a MEK/ERK-independent signaling
pathway.
3.4. EGF and FGF inhibit the IGF-I-induced IRS-1 tyrosine phosphorylation
and the IGF-I-stimulated PI 3-kinase activity by a Gö6976-sensitive
signaling pathway
PI 3-kinase can mediate the activation of several serine/threonine
kinases such as PKCs, some of which negatively regulate the IRS-1 ty-
rosine phosphorylation level [30]. To check whether PKCs could be
implicated in EGF- or FGF-induced inhibition of the IGF-I signaling
pathway, MCF-7 cells were preincubated for 1 h with well described
PKC/PKD1 inhibitors that help to discriminate between different
PKC isoforms [10,28], Gö6983 (inhibitor of PKCα, β, γ, δ, and ζ),
Gö6976 (inhibitor of PKCα, βI, and μ/PKD1) and GF109203X (inhibi-
tor of PKCα, βI, βII, γ, δ, and ε). Cells were then pretreated for
30 min with EGF or FGF, stimulated for 5 min with IGF-I and the tyro-
sine phosphorylation state of IRS-1 analyzed. As previously shown
(Fig. 1), IGF-I induced the tyrosine phosphorylation of IRS-1 and
EGF or FGF pretreatment inhibited this response (Fig. 4A). Interest-
ingly, this inhibition was totally impaired by Gö6976, whereas
Gö6983 and GF109203X had no effect (Fig. 4A). Speciﬁcity of these
results was conﬁrmed by demonstrating that none of the three inhibi-
tors affected basal and IGF-I-stimulated IRS-1 tyrosine phosphorylation
state (Fig. 4B).
Since the IGF-I-induced tyrosine phosphorylation of IRS-1 deter-
mines the activation of PI 3-kinase, we determined whether Gö6976
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Fig. 3. EGF and FGF inhibited the IGF-I-induced IRS-1 tyrosine phosphorylation by a PI 3-kinase-dependent and an ERK-independent signaling pathway. A. MCF-7 cells were pre-
incubated with or without wortmannin (100 nM) for 20 min as indicated and then pretreated or not with EGF (40 ng/mL) or FGF (5 ng/mL) for different periods of time (5–60 min)
prior being stimulated with IGF-I (22.5 ng/mL) for 5 min. Cells were lysed and proteins separated by SDS-PAGE, transferred to PVDF sheets and immunoblotted with anti-
phosphotyrosine or anti-actin antibodies as described in Materials and methods. The autoradiograms presented are those of typical experiments. Values, presented under each au-
toradiogram, represent quantitative analysis from three independent experiments of total tyrosine phosphorylated IRS-1 under each set of conditions, corrected for background,
and expressed relative to phosphotyrosylated IRS-1 measured after 5 min of IGF-I stimulation without any pretreatment with EGF or FGF (1.00). B. Same as in previous experiment
in which MCF-7 cells were preincubated with or without PD98059 (50 μM) for 1 h as indicated and then pretreated or not with EGF (40 ng/mL) or FGF (5 ng/mL) for 30 min prior
being stimulated with IGF-I (22.5 ng/mL) for 5 min. The autoradiogram presented is one of typical experiments. C. MCF-7 cells were preincubated with or without wortmannin
(100 nM) for 20 min as indicated and then pretreated or not with EGF (40 ng/mL) or FGF (5 ng/mL) for 30 min. Cells were lysed, proteins separated by SDS-PAGE, transferred to
PVDF sheets and immunoblotted with anti-phosphoAkt (P-Akt) or anti-ERK2 or anti-actinin antibodies as described in Materials and methods. The autoradiograms presented
are those of typical experiments.
562 M. Karam et al. / Biochimica et Biophysica Acta 1823 (2012) 558–569could also speciﬁcally reverse the inhibitory effect of EGF and FGF on
IGF-I-induced PI 3-kinase activity. Cells were preincubated for 1 h
with or without one of the three inhibitors, then incubated for
30 min with EGF or FGF prior to being stimulated for 5 min with
IGF-I. Cells were lysed and PI 3-kinase activity measured in immuno-
precipitates obtained with antibodies to IRS-1. As previously shown,
EGF or FGF pretreatment inhibited by 20–30% subsequent IGF-I-
induced IRS-1-associated PI 3-kinase activity (Fig. 5A and B). As might
be expected, Gö6976 totally reversed EGF- or FGF-induced inhibitionof IGF-I-stimulated PI 3-kinase activity whereas Gö6983 and
GF109203X had no effect (Fig. 5A and B). As previously, we checked
that the inhibitors did not affect the IGF-I-stimulated PI 3-kinase activity
(Fig. 5C). Similar results were obtained for total PI 3-kinase activity
measured in anti-p85 immunoprecipitates (data not shown).
Taken together, our results demonstrated that EGF and FGF inhibit
the IGF-I-induced IRS-1 tyrosine phosphorylation and the subsequent
IGF-I-stimulated PI 3-kinase activity by a Gö6976 sensitive, and
Gö6983 and GF109203X insensitive, signaling pathway.
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Fig. 4. EGF and FGF inhibit the IGF-I-induced IRS-1 tyrosine phosphorylation by a
Gö6976-sensitive signaling pathway. MCF-7 cells were preincubated with or without
Gö6983 (5 μM), Gö6976 (2.5 μM) or GF109203X (2.5 μM) for 1 h. A. Cells were then in-
cubated for 30 min with or without EGF (40 ng/mL) or FGF (5 ng/mL) prior to being
stimulated with IGF-I (22.5 ng/mL) for 5 min. Cells were, then, lysed and proteins sep-
arated by SDS-PAGE, transferred to PVDF sheets and immunoblotted with anti-
phosphotyrosine or anti-actin antibodies as described in Materials and methods. Auto-
radiograms presented are those of typical experiments conducted in duplicate. Values,
presented under each autoradiogram, represent quantitative analysis from three inde-
pendent experiments of total tyrosine phosphorylated IRS-1 under each set of condi-
tions, corrected for background, and expressed relative to phosphotyrosylated IRS-1
measured after 5 min of IGF-I stimulation without any pretreatment with EGF or FGF.
B. Same as in previous experiment in which cells were only stimulated for 5 min
with IGF-I (22.5 ng/mL). The autoradiogram presented is one of typical experiments.
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cells
According to the inhibitory spectra of the three respective inhibi-
tors tested at the concentrations used, our results strongly suggested
that EGF and FGF inhibited the IGF-I signaling pathway by a PKD1/
PKCμ dependent signaling pathway. To assess this hypothesis, we
ﬁrst checked whether EGF and FGF activated PKD1 in MCF-7 cells,
by western blot analysis using an anti-phospho-Ser744/748-PKD1 an-
tibody. As shown in Fig. 6A, PKD1 was similarly stimulated by EGF
and FGF with maximal activity occurring after 30 min of treatment
and remaining stable up to 60 min. Inhibition of PI 3-kinase by wort-
mannin did not impair EGF- or FGF-mediated activation of PKD1
(Fig. 6A) demonstrating that these two growth factors activated
PKD1 through a PI 3-kinase-independent signaling pathway. Inversely,
we also determined that EGF and FGF stimulated PI 3-kinase indepen-
dently of PKD1 (data not shown). Moreover, we showed that EGF- or
FGF-stimulated PKD1 was only totally inhibited by Gö6976 but never
altered by Gö6983 or GF109203X (Fig. 6B). This result conﬁrmed the
selectivity of the inhibitors used and strongly strengthened our
hypothesis.3.6. EGF and FGF inhibit the IGF-I signaling pathway by a PKD1-
dependent signaling pathway
To further conﬁrm these data obtained by a pharmacological ap-
proach and suggesting that EGF and FGF inhibit the IGF-I pathway
through PKD1, inhibition of PKD1 was also performed by transfecting
cells with speciﬁc PKD1-targeting (siPKD1) or control non-targeting
(siControl) siRNAs. As shown in Fig. 7A, PKD1 expression was
unchanged after transfection of MCF-7 cells with siControl but very
efﬁciently inhibited (about 78%, n=4) with siPKD1. Whereas siCon-
trol had no effect, siPKD1 transfection markedly diminished (about
83%) EGF- and FGF-induced inhibition of IGF-I-stimulated IRS-1 tyro-
sine phosphorylation (Fig. 7B). Similarly, EGF- and FGF-mediated in-
hibition of IGF-I stimulated PI 3-kinase signaling pathway, here
determined by phospho-Akt levels, was also impaired after siPKD1
transfection but unchanged with siControl (Fig. 7C). siPKD1 and
siControl affected neither IGF-I-stimulated IRS-1 tyrosine phosphory-
lation nor IGF-I-stimulated phospho-Akt, in the absence of EGF of FGF
pretreatment (data not shown). Taken together, these results con-
ﬁrmed previous data obtained with the pharmacological inhibitors
and demonstrated that EGF and FGF inhibit the IGF-I signaling path-
way through PKD1.3.7. PKD1 associates with IRS-1 in response to EGF and FGF
Since PKD1 is involved in the negative regulation of the IGF-I-
induced tyrosine phosphorylation of IRS-1, we asked whether these
two proteins could interact. Thus, proteins fromMCF-7 cells stimulat-
ed with EGF or FGF for different periods of time were immunoprecipi-
tated with anti-IRS-1 antibody, separated by electrophoresis and
immunodetected using anti-PKD1 antibody. In unstimulated cells, in-
teraction of PKD1 with IRS-1 was barely detectable (Fig. 8). However,
after 5 min of EGF or FGF treatment, PKD1 was observed in IRS-1 pull-
downs suggesting an interaction between these two proteins. This as-
sociation reached a peak at 15 and 30 min of FGF and EGF
pretreatment (maximal values of approximately 2.2- and 6-fold
over basal), respectively, and then remained stable up to 1 h.Whatever
the experimental conditions, we were not able to detect PKD1 in anti-
p85 immunoprecipitates (data not shown).3.8. EGF and FGF stimulate serine 307 phosphorylation of IRS-1 by a PI 3-
kinase-dependent but a PKD1-independent signaling pathway
The reduced IGF-I-stimulated tyrosine phosphorylation of IRS-1
could be a consequence of its phosphorylation on serine/threonine
residues and in particular on serine 307 [1]. Therefore, to check
whether EGF or FGF can modulate the phosphorylation state of this
residue, MCF-7 cells were stimulated for different periods of time
(5–60 min) with EGF or FGF before analysis of IRS-1 phosphorylation
on S307 residue. As shown in Fig. 9A, EGF and FGF strongly stimulated
the phosphorylation of IRS-1 on serine 307. Time course analysis
showed that, whatever the growth factor, this phosphorylation
was rapid (occurring after 5 min stimulation), reached maximal
values after 15–30 min of treatment, and remained elevated up to
1 h.
Implication of PI 3-kinase and PKD1 in EGF- and FGF-induced ser-
ine 307 phosphorylation of IRS-1 was therefore studied. Inhibition of
PI 3-kinase totally impaired the EGF- and FGF-induced serine 307
phosphorylation of IRS-1 (Fig. 9B). By contrast, inhibition of PKD1
by Gö6976 had no effect (Fig. 9C). Similar results were obtained in
cells transfected with siPKD1 (data not shown). Taken together,
these results demonstrated that the serine 307 phosphorylation of
IRS-1 induced by EGF and FGF is mediated by a PI 3-kinase-
dependent but a PKD1-independent signaling pathway.
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Fig. 5. EGF and FGF inhibit the IGF-I-induced IRS-1-associated PI 3-kinase activity by a Gö6976-sensitive signaling pathway. MCF-7 cells were preincubated with or without Gö6983
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Knowledge of the molecular mechanisms that regulate the IGF sig-
naling pathway is of major importance to develop novel and perti-
nent inhibitory strategies against the pro-proliferative signals
mediated by IGFs in tumors. In this study, we demonstrated that,
when cross-talks take place between tyrosine kinase receptor-
dependent signaling pathways, subtle regulatory processes occur at
the level of IRS-1 and subsequently affect downstream signals.
In fact, we showed that EGF or FGF treatment inhibited IGF-I-
induced IRS-1 tyrosine phosphorylation and, consequently, IRS-1
downstream signaling pathways by both a PI 3-kinase- and a PKD1-
dependent signaling pathways. PI 3-kinase has already been implicated
in the regulation of the insulin signaling pathway. It therefore appearsas an enzyme that possesses two opposite roles either positive, by me-
diating the biological effects of IGF in MCF-7 cells [19], or negative, by
inhibiting the IGF-I-induced IRS-1 tyrosine phosphorylation [27]. This
duality is of importance since, when recruited and activated by growth
factor-dependent signaling pathways different from the IGF one, PI 3-
kinase can therefore inhibit the IGF pathway even before binding of
IGF-I to its receptor. However, because several PI 3-kinase isoforms
exist, one may also hypothesize that this dual role would be the result
of the action of different members of this family. This hypothesis is cur-
rently under investigation.
We also demonstrated, by two different approaches, that speciﬁc
inhibition of PKD1 impaired the EGF- or FGF-induced negative regula-
tion of IRS-1 conferring to PKD1 a new major role in cross-talks that
take place between tyrosine kinase receptor dependent signaling
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Fig. 6. EGF and FGF activate PKD1 by a PI 3-kinase-independent signaling pathway. A. MCF-7 cells were preincubated with or without wortmannin (100 nM) for 20 min and then
stimulated or not for different periods of time (15–60 min) with EGF (40 ng/mL) or FGF (5 ng/mL). Cells were lysed and proteins separated by SDS-PAGE, transferred to PVDF sheets
and immunoblotted with anti-phospho-PKD1 or anti-PKD1 antibodies. Autoradiograms presented are those of typical experiments. Graphs represent quantitative analysis of
phospho-PKD1 under each set of conditions, corrected for background, and expressed relative to untreated cells (control). Results are the means±SEM for ﬁve independent exper-
iments (*, Pb0.01). B. MCF-7 cells were preincubated with or without Gö6983 (5 μM), Gö6976 (2.5 μM) or GF109203X (2.5 μM) for 1 h. Then, cells were incubated for 30 min with
or without EGF (40 ng/mL) or FGF (5 ng/mL). Cells were lysed and proteins separated by SDS-PAGE, transferred to PVDF sheets and immunoblotted with anti-phospho-PKD1 or
anti-PKD1 antibodies. Autoradiograms presented are those of typical experiments.
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downstream target of PI 3-kinase in IGF-stimulated multiple myelo-
ma cells [36], we showed that EGF or FGF activated PKD1 indepen-
dently of the PI 3-kinase pathway in MCF-7 cells. Since EGF and FGF
stimulate phospholipase Cγ in MCF-7 cells (data not shown), one
may suppose that PKD1 is activated, as usually described, by signal
transduction pathways initiated by diacylglycerol (DAG) [20,48,50].
Interestingly, we also demonstrated that the speciﬁc blockade of
PI 3-kinase or PKD1 (without affecting the other one) totally
prevented EGF- or FGF-induced inhibition of the IGF pathway.
Taken together, these results therefore indicated that PKD1 and
PI 3-kinase were activated by two different upstream signaling
pathways and that their simultaneous action was required for the
EGF- or FGF-induced inhibition of IGF-I-stimulated IRS-1 tyrosine
phosphorylation. Therefore, to our knowledge, it is the ﬁrst time
that the inhibitory action of PI 3-kinase, that occurs at the level of
IRS-1, was shown to necessarily require the concomitant activation
of another independent partner, i.e. PKD1.
IRS-1 serine 307 phosphorylation is a common mechanism en-
countered in the inhibitory processes of the insulin/IGF signaling
pathways [1–3]. According to this, we showed that EGF and FGF me-
diated the serine 307 phosphorylation of IRS-1 by a PI 3-kinase-
dependent signaling pathway. Although described as having serinekinase activity towards IRS-1 in vitro [22], PI 3-kinase may more cer-
tainly induce IRS-1 serine 307 phosphorylation by activating its
downstream partners and in particular p70/S6 kinase (for review
see [4]). By contrast to PI 3-kinase, EGF- or FGF-stimulated PKD1
did not phosphorylate IRS-1 on serine 307 indicating that this new
regulatory actor of IRS-1 did not act through the phosphorylation of
this residue. The molecular mechanisms by which PKD1 leads to the
inhibition of the IGF-I-induced tyrosine phosphorylation of IRS-1 re-
main to be determined. One may suggest that PKD1 could phosphor-
ylate IRS-1 on other serine residues. Nevertheless, even if currently
under investigation, this hypothesis seems unlikely since a PKD1 tar-
get sequence [31] was hardly identiﬁable into IRS-1 primary se-
quence [44] and because Gö6976 was shown not to inhibit the
insulin-induced serine phosphorylation of IRS-1 [35]. Moreover, al-
though PKD1 may activate ERK [15,41,46,54] which can phosphory-
late IRS-1 on serine 612 [5,6], this signaling pathway, and therefore
this serine phosphorylation, seemed improbable since we showed
that its blockade by the pharmacological inhibitor PD98056 did not
impair the EGF- or FGF-induced inhibition of the IGF pathway. Finally,
another hypothesis, that seems more likely without excluding the
previous ones, would be that PKD1 may affect IGF-I-induced IRS-1
tyrosine phosphorylation by a mechanism of allosteric competition.
In fact, we showed that EGF or FGF induced PKD1 association with
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were relatively faint, they were signiﬁcant and in accordance with
the low expression level of PKD1 in MCF-7 cells [7]. Thus, association
of PKD1 with IRS-1 might reduce the afﬁnity of the latter for IGF-IR
tyrosine kinase activity and consequently decrease its subsequent ty-
rosine phosphorylation. This last hypothesis can also be strengthened
by the fact that the time courses of PKD1 activation and of IRS-1 inhi-
bition are quite different. In fact, while the latter is maximal after
15 min of EGF or FGF pretreatment, PKD1 activity remains relatively
low and reaches its maximal value only after 30 min. By contrast, as-
sociation of PKD1 with IRS-1 is already maximally detected after
15 min of EGF or FGF pretreatment. This argument is obviously only
valid if one considers that PKD1 may have a maximal activity to effec-
tively inhibit IRS-1, that none of our results shows. Moreover, by mea-
suring PKD1 activity in whole cell lysates, it is also quite possible that
PKD1 activity would not be identical at any point into the cell and
that, after 15 min of stimulation with EGF or FGF, PKD1 would be
sufﬁciently stimulated in the vicinity of IRS-1 for efﬁcient inhibition
of the latter.
Taking into account these results, we propose the following model
to explain how PI 3-kinase and PKD1 might regulate the IGF signaling
in response to EGF and FGF (Fig. 10). When cells are only stimulated
by IGF-I (Fig. 10A), the IGF-IR induces the tyrosine phosphorylation of
IRS-1 which recruits docking proteins such as PI 3-kinase and initiates
speciﬁc IGF downstream signaling pathways. In cells pretreated with
EGF or FGF, the PI 3-kinase and PKD1 signaling pathways were acti-
vated (Fig. 10B). On the one hand, the PI 3-kinase pathway would
lead to serine 307 phosphorylation of IRS-1 whereas, on other hand,
PKD1 would interact with IRS-1 and perhaps phosphorylate it on an-
other residue. The concerted action of these two pathways would
therefore decrease the afﬁnity of IRS-1 towards the IGF-IR tyrosine ki-
nase activity and its subsequent tyrosine phosphorylation upon IGF-I
binding. The physiological outcomes of such signaling cross-talks re-
main to be determined. However, their impacts on “traditional” pro-
cesses such as cell proliferation appear difﬁcult to study. In fact,
regulatory mechanisms take place during longer time course analysis,
which modify IRS-1 protein expression levels and consequently the
downstream IGF-I signaling pathways [23]. However, one may
hypothesize that these inhibitory mechanisms that occur between0
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elements contributing to the signal speciﬁcity. In fact, by inhibiting the
other similar signaling pathways, theﬁrst bound (or themore potent) ac-
tivating growth factorwould give thereby further its signature to the cell.
It is absolutely noteworthy to observe the high similarity of the in-
hibitory time courses of IGF-I- or insulin-stimulated IRS-1-associated
PI 3-kinase activity induced by growth factor pretreatment in MCF-7
or in 3T3-L1 adipocytes [38] respectively. In fact, very characteristic
biphasic curves were again obtained in MCF-7 cells with a PI 3-
kinase activity associated with IRS-1 that returned to maximally
IGF-stimulated values after 15 or 30 min of growth factor pretreat-
ment. Although their signiﬁcance is still unknown, these data put in
evidence that a common and therefore relatively ubiquitous regulato-
ry mechanism exists for both the insulin and the IGF signaling path-
ways. Thus, it is conceivable to hypothesize that the regulatory
mechanisms we identiﬁed for the IGF signaling might also modulatethe insulin one and might explain some insulin resistance states.
The detected expression of PKD1 in insulin responsive tissues, such
as adipocytes [57], strengthens this hypothesis.
In conclusion, our results provide, for the ﬁrst time, evidence of a
coordinated action of two independent pathways to regulate the IGF
signaling at the level of IRS-1. They indicated that the described regula-
tory scheme of the IGF/insulin signaling by a feedback mechanism im-
plicating only the PI 3-kinase pathway is too simplistic and that
multiple partners need to be considered. As PI 3-kinase, PKD1 appears
as a regulatory protein which, by its ability to transform a short and
transitory signal to a more sustained one [29], represents an ideal can-
didate able to regulate several signaling pathways. Our results also illus-
trate the complexity and the speciﬁcity of the regulatory processes and
further demonstrate the necessity to take into account all these afferent
signals to develop efﬁcient therapeutic strategies against pathologies
such as cancers and diabetes.
A B
Fig. 10. Schematic model of the regulation of the IGF signaling pathway by PKD1. Panel A: Upon IGF binding, IGF-IR is activated and phosphorylates IRS-1 onto tyrosine (Y) residues
generating binding sites for docking proteins as PI 3-kinase which becomes activated andmediates the IGF signaling by stimulating its downstream targets such as Akt/PKB. Panel B:
EGF and FGF stimulate two independent signaling pathways that lead to the respective activation of PI 3-kinase and PKD1.Whereas PI 3-kinase induces the phosphorylation of IRS-1
onto serine (S) 307, PKD1 associates with IRS-1 and potentially (?) phosphorylates it onto distinct serine residues. These two events concomitantly prevent the further IGF-I-
induced tyrosine phosphorylation of IRS-1 and the subsequent IGF signaling pathway. See text for further details.
568 M. Karam et al. / Biochimica et Biophysica Acta 1823 (2012) 558–569Acknowledgements
This work was supported by the Centre National de la Recherche
Scientiﬁque, the Ecole Normale Supérieure de Cachan, the Université
Montpellier 2 and the Institut National de la Santé et de la Recherche
Médicale.
All authors declare no conﬂict of interest.
References
[1] V. Aguirre, T. Uchida, L. Yenush, R. Davis, M. White, The c-Jun NH(2)-terminal
kinase promotes insulin resistance during association with insulin receptor
substrate-1 and phosphorylation of Ser(307), J. Biol. Chem. 275 (2000)
9047–9054.
[2] V. Aguirre, E.D. Werner, J. Giraud, Y.H. Lee, S.E. Shoelson, M.F. White, Phosphory-
lation of Ser307 in insulin receptor substrate-1 blocks interactions with the insu-
lin receptor and inhibits insulin action, J. Biol. Chem. 277 (2002) 1531–1537.
[3] E. Arvisais, X. Hou, T.A. Wyatt, K. Shirasuna, H. Bollwein, A. Miyamoto, T.R. Hansen,
B.R. Rueda, J.S. Davis, Prostaglandin F2alpha represses IGF-I-stimulated IRS1/pho-
sphatidylinositol-3-kinase/AKT signaling in the corpus luteum: role of ERK and
P70 ribosomal S6 kinase, Mol. Endocrinol. 24 (2010) 632–643.
[4] S. Boura-Halfon, Y. Zick, Serine kinases of insulin receptor substrate proteins,
Vitam. Horm. 80 (2009) 313–349.
[5] K. De Fea, R. Roth, Modulation of insulin receptor substrate-1 tyrosine phosphoryla-
tion and function by mitogen-activated protein kinase, J. Biol. Chem. 272 (1997)
31400–31406.
[6] K. De Fea, R. Roth, Protein kinase C modulation of insulin receptor substrate-1 ty-
rosine phosphorylation requires serine 612, Biochemistry 36 (1997)
12939–12947.
[7] T. Eiseler, H. Doppler, I.K. Yan, S. Goodison, P. Storz, Protein kinase D1 regulates
matrix metalloproteinase expression and inhibits breast cancer cell invasion,
Breast Cancer Res. 11 (2009) R13.
[8] S. Giorgetti, R. Ballotti, A. Kowalski-Chauvel, M. Cormont, E. Van Obberghen, Insu-
lin stimulates phosphatidylinositol-3-kinase activity in rat adipocytes, Eur. J. Bio-
chem. 207 (1992) 599–606.
[9] B. Goldstein, Regulation of insulin receptor signaling by protein-tyrosine dephos-
phorylation, Receptor 3 (1993) 1–15.
[10] M. Gschwendt, S. Dieterich, J. Rennecke, W. Kittstein, H.J. Mueller, F.J. Johannes,
Inhibition of protein kinase C mu by various inhibitors. Differentiation from pro-
tein kinase c isoenzymes, FEBS Lett. 392 (1996) 77–80.
[11] P. Gual, T. Gonzalez, T. Gremeaux, R. Barres, Y. Le Marchand-Brustel, J.F. Tanti,
Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct
mechanisms in 3T3-L1 adipocytes, J. Biol. Chem. 278 (2003) 26550–26557.[12] P. Gual, Y. Le Marchand-Brustel, J.F. Tanti, Positive and negative regulation of
insulin signaling through IRS-1 phosphorylation, Biochimie 87 (2005) 99–109.
[13] T. Gustafson, W. He, A. Craparo, C. Schaub, T. O'Neill, Phosphotyrosine-dependent
interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the in-
sulin receptor via a novel non-SH2 domain, Mol. Cell. Biol. 15 (1995) 2500–2508.
[14] S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B.
Rosner, F.E. Speizer, M. Pollak, Circulating concentrations of insulin-like growth
factor-I and risk of breast cancer, Lancet 351 (1998) 1393–1396.
[15] A.Hausser, P. Storz, S.Martens, G. Link, A. Toker, K. Pﬁzenmaier, Protein kinaseD reg-
ulates vesicular transport by phosphorylating and activating phosphatidylinositol-4
kinase IIIbeta at the Golgi complex, Nat. Cell Biol. 7 (2005) 880–886.
[16] S.J. Heydrick, D. Jullien, N. Gautier, E. Van Obberghen, Y. Le Marchand-Brustel, De-
fect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant
mice, J. Clin. Invest. 91 (1993) 1358–1366.
[17] J.M. Holly, D.J. Gunnell, S.G. Davey, Growth hormone, IGF-I and cancer. Less inter-
vention to avoid cancer? More intervention to prevent cancer? J. Endocrinol. 162
(1999) 321–330.
[18] T. Ito, Y. Sasaki, J. Wands, Overexpression of human insulin receptor substrate 1
induces cellular transformation with activation of mitogen-activated protein ki-
nases, Mol. Cell. Biol. 16 (1996) 943–951.
[19] J.G. Jackson, M.F. White, D. Yee, Insulin receptor substrate-1 is the predominant
signaling molecule activated by insulin-like growth factor-I, insulin, and
interleukin-4 in estrogen receptor-positive human breast cancer cells, J. Biol.
Chem. 273 (1998) 9994–10003.
[20] F.J. Johannes, J. Prestle, S. Eis, P. Oberhagemann, K. Pﬁzenmaier, PKCu is a novel,
atypical member of the protein kinase C family, J. Biol. Chem. 269 (1994)
6140–6148.
[21] J.I. Jones, D.R. Clemmons, Insulin-like growth factors and their binding proteins:
biological actions, Endocr. Rev. 16 (1995) 3–34.
[22] K. Lam, C.L. Carpenter, N.B. Ruderman, J.C. Friel, K.L. Kelly, The phosphatidylinosi-
tol 3-kinase serine kinase phosphorylates IRS-1, J. Biol. Chem. 269 (1994)
20648–20652.
[23] C. Lassarre, J.M. Ricort, Growth factor-speciﬁc regulation of insulin receptor
substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-
like growth factor signaling pathway, Endocrinology 144 (2003) 4811–4819.
[24] B. Lavan, V. Fantin, E. Chang, W. Lane, S. Keller, G. Lienhard, A novel 160-kDa
phosphotyrosine protein in insulin-treated embryonic kidney cells is a new
member of the insulin receptor substrate family, J. Biol. Chem. 272 (1997)
21403–21407.
[25] B. Lavan, W. Lane, G. Lienhard, The 60-kDa phosphotyrosine protein in insulin-
treated adipocytes is a new member of the insulin receptor substrate family,
J. Biol. Chem. 272 (1997) 11439–11443.
[26] A.V. Lee, J.L. Gooch, S. Oesterreich, R.L. Guler, D. Yee, Insulin-like growth factor I-
induced degradation of insulin receptor substrate 1 is mediated by the 26S pro-
teasome and blocked by phosphatidylinositol 3′-kinase inhibition, Mol. Cell.
Biol. 20 (2000) 1489–1496.
569M. Karam et al. / Biochimica et Biophysica Acta 1823 (2012) 558–569[27] J. Li, K. DeFea, R. Roth, Modulation of insulin receptor substrate-1 tyrosine phos-
phorylation by an Akt/phosphatidylinositol 3-kinase pathway, J. Biol. Chem. 274
(1999) 9351–9356.
[28] G. Martiny-Baron, M.G. Kazanietz, H. Mischak, P.M. Blumberg, G. Kochs, H. Hug, D.
Marme, C. Schachtele, Selective inhibition of protein kinase C isozymes by the
indolocarbazole Go 6976, J. Biol. Chem. 268 (1993) 9194–9197.
[29] S.A. Matthews, T. Iglesias, E. Rozengurt, D. Cantrell, Spatial and temporal regula-
tion of protein kinase D (PKD), EMBO J. 19 (2000) 2935–2945.
[30] A.C. Newton, Regulation of the ABC kinases by phosphorylation: protein kinase C
as a paradigm, Biochem. J. 370 (2003) 361–371.
[31] K. Nishikawa, A. Toker, F.J. Johannes, Z. Songyang, L.C. Cantley, Determination of
the speciﬁc substrate sequence motifs of protein kinase C isozymes, J. Biol.
Chem. 272 (1997) 952–960.
[32] T. Noguchi, T. Matozaki, K. Horita, Y. Fujioka, M. Kasuga, Role of SH-PTP2, a
protein-tyrosine phosphatase with Src homology 2 domains, in insulin-
stimulated Ras activation, Mol. Cell. Biol. 14 (1994) 6674–6682.
[33] Y.I. Oh, J.H. Kim, C.W. Kang, Involvement of insulin-like growth factor-I secretion
and all-trans-retinoic acid-induced decrement in viability in MCF-7 cells, Chemo-
therapy 57 (2011) 17–26.
[34] K. Paz, R. Hemi, D. LeRoith, A. Karasik, E. Elhanany, H. Kanety, Y. Zick, A molecular
basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1
and IRS-2 inhibits their binding to the juxtamembrane region of the insulin re-
ceptor and impairs their ability to undergo insulin-induced tyrosine phosphory-
lation, J. Biol. Chem. 272 (1997) 29911–29918.
[35] K. Paz, Y. Liu, H. Shorer, R. Hemi, D. LeRoith, M. Quan, H. Kanety, R. Seger, Y. Zick,
Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B posi-
tively regulates IRS-1 function, J. Biol. Chem. 274 (1999) 28816–28822.
[36] Y.W. Qiang, L. Yao, G. Tosato, S. Rudikoff, Insulin-like growth factor I induces mi-
gration and invasion of human multiple myeloma cells, Blood 103 (2004)
301–308.
[37] J. Rennecke, P.A. Rehberger, G. Furstenberger, F.J. Johannes, M. Stohr, F. Marks,
K.H. Richter, Protein-kinase-Cmu expression correlates with enhanced keratino-
cyte proliferation in normal and neoplastic mouse epidermis and in cell culture,
Int. J. Cancer 80 (1999) 98–103.
[38] J.-M. Ricort, J.-F. Tanti, E. Van Obberghen, Y. Le Marchand-Brustel, Cross-talk be-
tween the platelet-derived growth factor and the insulin signaling pathways in
3T3-L1 adipocytes, J. Biol. Chem. 272 (1997) 19814–19818.
[39] E. Rozengurt, O. Rey, R.T. Waldron, Protein kinase D signaling, J. Biol. Chem. 280
(2005) 13205–13208.
[40] S. Sciacchitano, S. Taylor, Cloning, tissue expression, and chromosomal localiza-
tion of the mouse IRS-3 gene, Endocrinology 138 (1997) 4931–4940.
[41] J. Sinnett-Smith, E. Zhukova, N. Hsieh, X. Jiang, E. Rozengurt, Protein kinase D
potentiates DNA synthesis induced by Gq-coupled receptors by increasing the
duration of ERK signaling in swiss 3T3 cells, J. Biol. Chem. 279 (2004)
16883–16893.
[42] J. Smith-Hall, S. Pons, M. Patti, D. Burks, L. Yenush, X. Sun, C. Kahn, M. White, The
60 kDa insulin receptor substrate functions like an IRS protein (pp 60IRS3) in adi-
pose cells, Biochemistry 36 (1997) 8304–8310.[43] P. Storz, A. Toker, Protein kinase D mediates a stress-induced NF-kappaB activa-
tion and survival pathway, EMBO J. 22 (2003) 109–120.
[44] X.J. Sun, P. Rothenberg, C.R. Kahn, J.M. Backer, E. Araki, P.A. Wilden, D.A. Cahill, B.J.
Goldstein, M.F. White, Structure of the insulin receptor substrate IRS-1 deﬁnes a
unique signal transduction protein, Nature 352 (1991) 73–77.
[45] X.J. Sun, L.-M. Wang, Y. Zhang, L. Yenush, M.G. Myers Jr., E. Glasheen, W.S. Lane,
J.H. Pierce, M.F. White, Role of IRS-2 in insulin and cytokine signaling, Nature
377 (1995) 173–177.
[46] C. Torricelli, G. Valacchi, E. Maioli, Novel PKCs activate ERK through PKD1 in MCF-
7 cells, In Vitro Cell. Dev. Biol. Anim. 47 (2011) 73–81.
[47] A. Ullrich, A. Gray, A.W. Tam, T. Yang-Feng, M. Tsubokawa, C. Collins, W. Henzel, T.
Le Bon, S. Kathuria, E. Chen, S. Jacobs, U. Francke, J. Ramachandran, Y. Fujita-
Yamaguchi, Insulin-like growth factor I receptor primary structure: comparison
with insulin receptor suggests structural determinants that deﬁne functional
speciﬁcity, EMBO J. 5 (1986) 2503–2512.
[48] A.M. Valverde, J. Sinnett-Smith, L.J. Van, E. Rozengurt, Molecular cloning and charac-
terization of protein kinase D: a target for diacylglycerol and phorbol esters with a
distinctive catalytic domain, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8572–8576.
[49] J.V. Van Lint, J. Sinnett-Smith, E. Rozengurt, Expression and characterization of
PKD, a phorbol ester and diacylglycerol-stimulated serine protein kinase, J. Biol.
Chem. 270 (1995) 1455–1461.
[50] Q.J. Wang, PKD at the crossroads of DAG and PKC signaling, Trends Pharmacol. Sci.
27 (2006) 317–323.
[51] E.D. Werner, J. Lee, L. Hansen, M. Yuan, S.E. Shoelson, Insulin resistance due to
phosphorylation of insulin receptor substrate-1 at serine 302, J. Biol. Chem. 279
(2004) 35298–35305.
[52] M. White, The insulin signalling system and the IRS proteins, Diabetologia 40
(Suppl 2) (1997) 2–17.
[53] C. Wong, Z.G. Jin, Protein kinase C-dependent protein kinase D activation modu-
lates ERK signal pathway and endothelial cell proliferation by vascular endothe-
lial growth factor, J. Biol. Chem. 280 (2005) 33262–33269.
[54] C. Wong, Z.G. Jin, Protein kinase C-dependent protein kinase D activation modu-
lates ERK signal pathway and endothelial cell proliferation by vascular endothe-
lial growth factor, J. Biol. Chem. 280 (2005) 33262–33269.
[55] L. Yenush, K. Makati, J. Smith-Hall, O. Ishibashi, M.J. Myers, M. White, The pleck-
strin homology domain is the principal link between the insulin receptor and
IRS-1, J. Biol. Chem. 271 (1996) 24300–24306.
[56] C. Yu, Y. Chen, G.W. Cline, D. Zhang, H. Zong, Y. Wang, R. Bergeron, J.K. Kim, S.W.
Cushman, G.J. Cooney, B. Atcheson, M.F. White, E.W. Kraegen, G.I. Shulman,
Mechanism by which fatty acids inhibit insulin activation of insulin receptor
substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle,
J. Biol. Chem. 277 (2002) 50230–50236.
[57] Y. Zhou, D. Wang, F. Li, J. Shi, J. Song, Different roles of protein kinase C-betaI and
-delta in the regulation of adipocyte differentiation, Int. J. Biochem. Cell Biol. 38
(2006) 2151–2163.
[58] E. Zhukova, J. Sinnett-Smith, E. Rozengurt, Protein kinase D potentiates DNA syn-
thesis and cell proliferation induced by bombesin, vasopressin, or phorbol esters
in Swiss 3T3 cells, J. Biol. Chem. 276 (2001) 40298–40305.
